In this study we investigated the expression of the two cyclooxygenases, cox-1 and -2, in sheep uterine tissues during the estrous cycle and early pregnancy. We identified the cox-2 isoform in the ovine uterus by Western blot and demonstrated that the two cyclooxygenases exhibited different patterns of expression. Cox-1 was expressed at steady state levels in the endometrium during the estrous cycle and comparable stages of pregnancy. In contrast, cox-2 was highly and transiently expressed from days 12-15 of the estrous cycle and declined thereafter to undetectable levels. Endometrium from early pregnant ewes showed a similar pattern of cox-2 expression, although there was a slower decrease beyond day 15. Immunohistochemical studies demonstrated that cox-1 was localized in both epithelial and stromal cells, whereas cox-2 was localized solely in the luminal epithelium and to a lesser extent in the superficial glands. Treatment of ovariectomized ewes with steroids indicated that expression of cox-1 remained at constant levels whatever the treatment. In contrast, endometrial cox-2 was highly induced by a 10-day progesterone treatment. Estradiol slightly increased cox-2 expression but only after progesterone priming. Collectively these results suggest that the developing ability of the uterus to synthesize PGs is due to the induction of cox-2. (Endocrinology 138: [2163][2164][2165][2166][2167][2168][2169][2170][2171] 1997) I N RUMINANTS, the uterus is the site of a sizable increase in the synthesis of PGF2␣ during the luteolytic phase of the estrous cycle. During luteolysis PGF2␣ is secreted in a series of high-amplitude, short duration pulses (1, 2) in response to peaks in luteal oxytocin secretion (for review see Ref.
I
N RUMINANTS, the uterus is the site of a sizable increase in the synthesis of PGF2␣ during the luteolytic phase of the estrous cycle. During luteolysis PGF2␣ is secreted in a series of high-amplitude, short duration pulses (1, 2) in response to peaks in luteal oxytocin secretion (for review see Ref. 3) . In early pregnancy the loss of the uterine responsiveness to oxytocin causes the suppression of the pulsatile pattern of PGF2␣ secretion and results in corpus luteum maintenance (reviewed Ref. 4 and 5) . However, the level of basal secretion of PGs is enhanced. The mechanism by which the oxytocin receptor is suppressed in pregnant ewes is partially understood. Interferon-, a 20-kDa protein that is produced by the trophectoderm of the ovine conceptus between days 10 -21 (6, 7) , inhibits the endometrial estrogen receptor and consequently prevents the estrogen-induced increase in oxytocin receptor number (8) . Despite alterations in the dynamics of PGF2␣ secretion, the uterus maintains the same ability to synthesize PGF2␣ during the luteal phase of estrous cycle and in comparable stages of early pregnancy.
Other reports have shown that the increase in the ability of the uterus to synthesize PGs corresponds to changes in the PG synthase enzyme, which converts arachidonic acid into PGs. In sheep, Huslig et al. (9) demonstrated that the increase in PGF2␣ that occurs around the time of luteolysis corresponds to an 8-fold increase in the concentration of uterine PG synthase. However, these changes in enzyme protein were not reflected at the messenger RNA (mRNA) level (10) . No significant differences were seen in PG synthase mRNA concentrations analyzed by Northern blot throughout the estrous cycle. This discrepancy could be explained by an increase in the translation rate of the protein despite the steady state levels of mRNA transcripts. The extension of the half-life of the enzyme may also account for the enhanced PG synthase concentration. However, we hypothesize that the apparent conflicting results between the levels of enzyme protein and mRNA reflect the existence of two distinct types of PG synthase. Actually, two isoforms of PG synthase have been recently identified: cyclooxygenase-1 (cox-1) and cyclooxygenase-2 (cox-2) (for review see Refs. 11 and 12) . The apparent molecular weight of the two isoforms is nearly 72 kDa on a SDS-PAGE gel. The additional sites of glycosylation on cox-2 give rise to an second band at 74 kDa (13) . Deduced amino acid sequences showed approximately 60% homology between the two isoforms within species, whereas 90% homology was observed among the cox-2 of different species (14) . The cox-2 sequence contains an additional 18-amino acid insert in the C-terminal region as compared with the sequence of cox-1. This short 18-amino acid tail made it possible to raise specific antibodies against cox-2 (15, 16).
Moreover, the cyclooxygenases differ in their pattern of expression (for review see Refs. 17 and 18) . Cox-1 is a constitutive enzyme that is expressed in many tissues to ensure the synthesis of PGs for the so-called housekeeping functions (17) . In contrast, cox-2 is an inducible enzyme that is normally absent from cells and appears as an early responsive gene triggered by a wide variety of factors [mitogens (19, 20) , interleukin-1 (15, 21) , and growth factor (22) ]. Cox-2 has been implicated in reproductive events such as ovulation, embryo implantation, and parturition. It is induced in rat (23, 24) and bovine (25) follicles at the time of ovulation under hormonal stimulation. Cox-2 is also expressed at the time of blastocyst implantation in the rat uterus (26, 27) and in human decidua (28) . In sheep, cox-2 is strongly induced in the placenta at the onset of parturition (29 -31) .
This study was designed to determine whether the ovine endometrium expresses cox-2 during the estrous cycle and early pregnancy and to characterize the cell types containing the PG synthase isoforms. Moreover, it has been reported that estradiol and progesterone exert pronounced effects on the release of endometrial PGF2␣ from explants (32) and cultured cells (33) , suggesting a direct effect of the ovarian steroids on PG synthase. We examined the developmental and hormonal regulation of the two cyclooxygenases using steroid replacement treatments in ovariectomized ewes.
Materials and Methods

Source of animals and tissue collection
All procedures relating to the care and use of animals were approved by the French Ministry of Agriculture according to the French regulations (instruction 19/04/1988) for animal experimentation.
Cyclic and pregnant ewes. Ewes of the Préalpes-du-Sud breed were used. Estrus was synchronized using intravaginal sponges containing 60 mg 6␣-methyl-17␣-acetoxyprogesterone for 14 days as previously described by Peterson et al. (34) . On the day of sponge withdrawal, ewes received one injection im of 500 IU PMSG. Estrus was observed 48 h later (day 0 of the cycle), and those assigned to be pregnant were mated. On days 6, 9, 12, 15, and 17 of the estrous cycle or pregnancy, the ewes were slaughtered. Five ewes at each stage of estrous cycle or pregnancy were used. The uterus was removed and excised. Conceptuses from mated ewes were removed by flushing the uterine horns to confirm pregnancy. A piece of the uterine horn ipsilateral to the corpus luteum was preserved for immunocytochemical analysis. The endometrium was separated from the myometrial layer by dissection. Five hundred milligrams (wet wt) of the endometrium were reserved for explant production. The remaining endometrium and myometrium were frozen in liquid nitrogen and stored at Ϫ80 C until further analysis.
Steroid-treated ovariectomized ewes. Twenty-one ewes were ovariectomized via midventral laparotomy under general anesthesia and were allowed to recover for 4 weeks. The ewes were then randomly allocated to three control groups and four experimental groups (3 animals/group) and were given progesterone and estradiol according to a protocol (35) aimed at mimicking the changes in steroid plasma concentrations observed during an estrous cycle. Day 0 was the day of the beginning of the steroid treatment and day Ϫ12 was the day of the beginning of the steroid pretreatment. All ewes were killed on day 12. Ewes of the three control groups were treated as described below. Group C, which was the nontreated ovariectomized control group, was exposed to no treatment from days Ϫ12-0, and exposed to im injections of 1 ml vehicle twice daily from day 1 to slaughter on day 12. Group C-P was exposed to intravaginal sponges containing 60 mg 6␣-methyl-17␣-acetoxyprogesterone from days Ϫ12 to Ϫ1, followed by im injections of 1 ml vehicle twice daily from days Ϫ1-12. Group C-E was exposed to intravaginal sponges containing 60 mg 6␣-methyl-17␣-acetoxyprogesterone from days Ϫ12 to Ϫ1, followed by four im injections of 25 g estradiol at 12-h intervals on days Ϫ1 and 0, and im injections of 1 ml vehicle twice daily from days 1-12. The animals of the four experimental groups were primed for 12 days (days Ϫ12-0) by exposure to intravaginal sponges containing 60 mg 6␣-methyl-17␣-acetoxyprogesterone, followed by four im injections of 25 g estradiol at 12-h intervals on days Ϫ1 and 0. Then the ewes received various combinations of progesterone and estradiol injections as described below. Group P10 received im injections of progesterone at 12-h intervals from days 1-10, then im injections of 1 ml vehicle twice daily for days 11 and 12. Group P10-E was treated as group P10 and followed by four im injections of 25 g estradiol at 12-h intervals on days 11 and 12. Group P12 was exposed to im injections of progesterone at 12-h intervals from days 1-12. Group P12-E was treated as group P12 plus four im injections of 25 g estradiol at 12-h intervals on days 11 and 12. Progesterone, when given, was administrated im, 2 mg/injection on days 1-2, 5 mg/injection on days 3 and 4, and 10 mg/injection from day 5 until the end of the treatment. Both estradiol and progesterone were administrated in 1 ml 90% corn oil/10% ethyl alcohol (i.e. vehicle). All ewes were killed from 4 -6 h after the last injection on day 12. The uteri were excised and each endometrium was separated from the myometrium and frozen in liquid nitrogen.
PGF2␣ production by endometrial explants. Explants (300 mg wet wt) of endometrium were randomly distributed into three dishes containing 10 ml Ham's-F12 culture medium. The explants were rinsed twice for 15 min with fresh medium and were incubated for 6 h at 38 C under 5% CO 2 in humidified air. The amount of PGF2␣ produced by the explants was measured in the culture medium by RIA as previously described (36) . Briefly, an assay was conducted using raioiodinated tracers of PGF2␣-histamine derivative. Concentrations of PGF2␣ were determined in duplicate in unextracted medium samples, using an anti-PGF2␣ antibody purchased from Pasteur-Productions (Paris, France). To 5-ml tubes were added 0.1 ml iodinated tracer (20,000 dpm), 0.1 ml PFG2␣ standard or culture medium sample, and 0.1 ml of a dilution of the antiserum such that the initial binding in the absence of standard was 40% of the total radioactivity. Iodinated tracer, PGF2␣ standards, and samples were diluted in 0.1 m phosphate-buffer, pH 7.3, containing 0.9% NaCl and 0.3% bovine ␥-globulin. Incubation was conducted overnight at 4 C. Free and bound radioactivity were separated by adding successively 0.1 ml of a dilution of antirabbit IgG and 1 ml polytethylene glycol 6000 (10% wt/vol) containing 0.4% CaCl2, and centrifugating at ϩ4 C for 15 min at 3000 ϫ g. The pellet was counted for 1 min in a ␥-counter. Calculation of the standard curve and unknown samples was performed on computer using the logit method. The sensitivity of the assay was defined as the quantity of PGF2␣ necessary to give 50% displacement of B0 and was 12 pg/tube. The interassay coefficient of variation was 14%, and intraassay coefficient of variation ranged from 8 -12%. The PGF2␣ production by each endometrium was defined as the mean production determined from three dishes and was expressed in nanograms per milligram wet tissue.
Microsome preparation
Frozen tissues were weighed, thawed, and maintained at 4 C throughout all the manipulations. The tissues (10 -15 g wet wt) were homogenized in 50 ml 50 mm Tris-HCl, pH 8.0, containing 250 mm saccharose, 10 mm EDTA, 1 mm diethyldithiocarbamate, 1 mm benzamidine-HCl, and 10 g/ml soybean trypsin inhibitor using a polytron homogenizer (Kinematica, Switzerland). Homogenates were filtered through gauze and centrifuged at 8000 ϫ g for 20 min at 4 C. The supernatant was centrifuged at 100,000 ϫ g for 60 min at 4 C. The pellet was resuspended in 300 l 0.25% SDS solution. The suspended microsomes were stored at Ϫ80 C until Western blot analysis. The protein content of the microsome preparation was determined in triplicate by the method of Peterson et al. (37) with BSA as the standard.
Western blot analysis of cox-1 and -2
Microsome samples equivalent to 15 g total protein were mixed with Laemmli reagent (vol/vol) under reducing conditions (5% 2-mercaptoethanol) and heated for 10 min at 85 C. Proteins were separated in a 10% SDS-PAGE using the miniprotean II system from Bio-Rad (Ivry, France). Separation was carried out under a constant current (15 mA/gel of 0.75 mm thickness). The Rainbow molecular weight markers from Amersham (les Ulis, France) were used as molecular weight standards. Proteins were transferred onto 0.1 m nitrocellulose membranes for 2 h at 250 mA, in a 25 mm Tris buffer, pH 8.2, 192 mm glycine containing 0.1% SDS and 15% methanol. Blots were stained with 0.5% Ponceau Red in 0.3% trichloroacetic acid for a loading control for each sample. Blots were performed in duplicate under the same conditions, one for cox-1 analysis and the other for cox-2 analysis.
Membranes were saturated overnight at 4 C with 5% fat-free dry milk in 50 mm Tris-HCl, pH 7.5, containing 250 mm NaCl and 0.1% Tween 20 (TBS-TM buffer). The membranes were then incubated with anticox-1 or anticox-2 antibodies diluted in the TBS-TM buffer. The antibodies used in this study were prepared as previously described (15, 16) . The mouse anticox-2 monoclonal antibody (mAb294) was raised against the peptide C-NASSSRSGLDDINPTVLLK (cox-2 peptide), which is present in the carboxyl-terminus of human cox-2 and absent in the cox-1 protein.
The rabbit anticox-1 polyclonal antibody (L855) was raised against cox-1 purified from ram seminal vesicles. A more detailed description of anticox-1 and anticox-2 antibodies has been reported by Créminon et al. (16) . The mAb294 and L855 antibodies were used at a concentration of 3 g/ml and 1:3000 dilution in TBS-TM (0.2 ml/cm 2 ), respectively. The incubation was performed for 1 h at room temperature. Blots were washed twice for 10 min in the TBS-TM buffer and three times for 15 min in the TBS-TM buffer without milk (TBS-T buffer). Membranes were further incubated for 1 h at room temperature with anti-IgG antibodies conjugated with horseradish peroxidase at 1:3000 dilution in TBS-T buffer. Excess of the second antibody was eliminated by extensive washes in TBS-T buffer (5 consecutive 10-min washes). Chemiluminescent substrate was used according to the manufacturer's instructions (ECL Kit, Amersham) and immunoreactive proteins were visualized after 1-5 min exposure to hyperfilm-ECL (Amersham). Immunoreaction signals were quantified on the films by scanning densitometry using an image analysis system (M-Lecphor, Biocom, les Ulis, France). To correct for variations in the intensity of the Western blot staining, one endometrium extract was used as internal standard and put on each gel.
Immunohistochemistry
Part of the uterine horn ipsilateral to the corpus luteum was cross sectioned into 1-cm long pieces. Tissue pieces were immersed in ice-cold isopentane, snap frozen in liquid nitrogen, and stored at Ϫ80 C. All endometrium pieces were sectioned in 6-to 8-m slices using a Frigocut cryostat (Reichert-Jung, Paris, France). Slices were collected on microscope slides (Super-Frost/Plus, C.M.L., Nemours, France), dried in air, and stored at Ϫ20 C. Frozen tissue slices were fixed for 15 min in a cold 4% paraformaldehyde solution and washed twice for 5 min with 0.1 m PBS, pH 7.2, 0.1 m glycine for rehydration. Slices were incubated for 1 h with 100 l nonimmune goat serum (1:10 dilution) in 0.1 m PBS containing 0.2% BSA. Sections were then incubated for 1 h at room temperature in a humidified atmosphere with the anticox-2 monoclonal antibody mAb294 (2.5 g/100 l) or anticox-1 polyclonal antibody L855 (1:20 dilution), which were diluted in 0.1 m PBS containing 2% BSA. Control sections from each tissue were incubated with the primary antibodies adsorbed with the respective antigen or were incubated with nonimmune rabbit serum or with incubation buffer alone. After three washes of 15 min with 0.1 m PBS containing 0.2% BSA, the sections were incubated for 1 h at room temperature, in darkness, and in a humidified atmosphere with anti-IgG antibodies conjugated to fluorescein isothiocyanate and previously diluted at 1:200 in 0.1 m PBS containing 2% BSA. The slides were washed once for 15 min in 0.1 m PBS containing 0.2% BSA with Hoescht's dye (1:500 dilution) for chromatogen coloration. Slides were then washed twice for 15 min in the same buffer without Hoescht's dye. Finally, they were rinsed in 0.1 m Tris-HCl buffer, pH 8.0, and covered with Mowiol (Hoescht France, Paris, France). All sections were examined for specific fluorescence using a Reichert microscope equipped with an epifluorescence illuminating system. Microphotographs were taken on Fuji film (Sensia, 400 ASA, Photoservice, Velizy, France). The same exposure time was used for both control and experimental sections.
Statistical analysis
ANOVA was used to tested effect of day, status, and steroid treatments on relative amounts of immunoreactive cyclooxygenase in the endometrium. Differences between individual means were assessed by the Student-Newman-Keuls multiple range test. Correlations between the PGF2␣ concentration and cox-2 or -1 contents were analyzed by the Pearson product moment test.
Results
Uterine cox-1 and -2
The Western blot shown in Fig. 1 revealed cox-1 in the endometrium and in the myometrium of the ovine uterus. However, as indicated by the intensity of the chemiluminescent signal, higher concentrations of the enzyme were present in the myometrium than in the endometrium. In contrast, the mAb 294 revealed cox-2 in the endometrium but not in the myometrium (Fig. 2) .
The specificity of the two enzymes detected by the antibodies was confirmed by immunoadsorption tests. The mAb anti-cox2 mAb294 revealed a band at 70 kDa, which was identified as cox-2. The immunoadsorption of mAb294 by the peptide corresponding to the C-terminal sequence of cox-2 resulted in the disappearance of the 70-kDa band (Fig. 2B) . This occurred for both the cox-2 standard preparations and the uterine extracts, confirming the identity of the protein.
The additional protein that was revealed at 60 kDa did not correspond to the binding of the primary antibody. This band was displayed when the second antibody was added to the nitrocellulose membrane without previous incubation with primary antibody (data not shown).
The immunoadsorption of anticox-1 polyclonal antibody with PG synthase from ram seminal vesicles led to the disappearance of the protein band for standard cox-1 and ovine tissues (Fig. 2B) . A weak signal did remain, however. Higher concentrations of the PG synthase protein were required to completely neutralize the polyclonal antibody L855. The inconvenience of such a protocol is that it induced high background levels, making it impossible to analyze the immunoblot.
As determined by denaturating electrophoresis, the molecular mass of cox-2 (70 kDa) from the ovine endometrium was consistent with previously published data. In some blots ovine endometrial cox-2 may be resolved as a doublet similar to that observed in the sheep placenta (29) , in the bovine ovary (25) , and in the rat preovulatory follicles (24) , as well as in other mammal cells.
Cox-1 and -2 during the estrous cycle and early pregnancy
The cyclooxygenases were analyzed in ovine endometrium by Western blots on days 6, 9, 12, 15, and 17 of the estrous cycle (Fig. 3) and on days 9, 12, 15, and 17 of pregnancy (Fig. 4) . Endometrial extracts of five ewes were analyzed. The blots from two are shown by day of collection.
Cox-1 was detected in the endometrium at all stages of the estrous cycle and early pregnancy. Using five ewes from each status, the determination of the cox-1 content by densitometric integration of the protein bands showed no significant variation throughout the estrous cycle or early pregnancy. However, a significant difference in the mean values between pregnant and cyclic animals was observed. Cox-1 in the nonpregnant endometrium was 1.5 times higher than in the pregnant one (P ϭ 0.002).
In nonpregnant ewes, cox-2 was detected by day 12, remained highly expressed through day 15, and became barely detectable on day 17. Similarly, in pregnant ewes, cox-2 was first detected on day 12 but was still expressed on day 17. Thereafter the amount of cox-2 decreased progressively up to day 25 of pregnancy (data not shown). The quantification of protein bands by scanning densitometry allowed the patterns of the cox-2 expression during the estrous cycle and early pregnancy to be compared (Fig. 5) . In both cases the cox-2 concentration was maximal on day 12 and then decreased. There was a statistically significant difference in the mean values among the days of the estrous cycle or pregnancy (P Ͻ 0.001). No overall difference was demonstrated between the two endocrine statuses (P ϭ 0.128). However, on day 17, the cox-2 content of the pregnant endometrium was statistically different from that of the nonpregnant tissue (P ϭ 0.025).
Immunohistochemical localization of cox-1 and -2
The cellular localization of cox-2 in the ovine uterus during the estrous cycle is illustrated in Fig. 6 , A-D. On day 12, immunoreactivity was demonstrated in the entire caruncular epithelium, whereas in the intercaruncular epithelium cox-2 was not present (Fig. 6A) or only sparsely distributed. On day 15 both the caruncular and interca- runcular epithelia were stained (Fig. 6B ). The uterine glands displayed different degrees of staining according to their location within the endometrium (Fig. 6C) . Only the glands close to the uterine lumen showed detectable cox-2 levels. No immunoreactivity was seen in the deeper glands (Fig. 6D) . There was no detectable staining in the stromal endometrium nor in the myometrium. No positive immunoreactivity was observed in control sections (not shown). No difference in immunostaining was observed between pregnant and nonpregnant endometria. To ensure that the polyclonal antibody against cox-1 did not cross-react with cox-2, the localization of cox-1 was performed on day 9 endometrium only, because cox-2 was not expressed at this stage (Fig. 3) . The localization of immunopositive cells for cox-1 is shown in Fig. 6 , E and F. Cox-1 was observed in both the luminal and the glandular epithelium, and a weak staining of the stromal cells underlying the epithelium was also seen (Fig. 6F) . Moreover, cox-1 was present in the deeper glands of the endometrium (Fig. 6E) . No differences were seen between pregnant and nonpregnant ewes. Figure 7 shows the PGF2-␣ production levels in the culture medium by endometrial explants in relation to concentration of cyclooxygenases. There was no detectable relationship between the cox-1 concentration and the amount of PGF2␣ released (R ϭ 0.002; P ϭ 0.995). However, the PGF2␣ accumulation in the culture medium increased as the cox-2 level increased in the endometrium (R ϭ 0.793; P ϭ 0.011). These data did not provide information concerning the respective contribution of each of the two isoforms to PG production. However, this result suggested that the ability of endometrium tissue to produce different amounts of PGs was due to modifications in the concentration of cox-2.
PGF2␣ release by endometrium explants
Control of endometrial cyclooxygenases by steroids
The observation that cox-2 showed marked cyclical changes throughout the estrous cycle led us to examine the role of steroids on the expression of the two cyclooxygenases. The effects of steroid treatment on endometrial cyclooxyge- nases of ovariectomized ewes are presented in Fig. 8 . Cox-1 was observed in all the control and treated groups, although the concentration of the protein differed between groups (P ϭ 0.012). There was no difference between the 10-day progesterone treatment (group P10) and the three control groups (C, C-P, C-E). In contrast, administration of progesterone for 12 days (group P12) resulted in a significant increase in cox-1 level (P Ͻ 0.001). Estradiol never caused any modifications in the cox-1 concentration. Cox-2 was not detected in the endometrium from control ovariectomized ewes (group C) nor in the steroid pretreatment groups (groups C-P, C-E). However cox-2 was strongly induced in all the steroid treatment groups. There was a significant increase of the enzyme by the 12-day treatment (group P12) vs. the 10-day treatment (group P10) (P ϭ 0.001). Administration of estradiol for 2 days after the 10-day progesterone (group P10-E) treatment did not alter the cox-2 concentration. When estradiol was given in combination with progesterone on days 11 and 12 (group P12-E), an additional increase in cox-2 seemed to result, but the increase was not statistically significant as indicated by examination of the densitometric data.
Discussion
The present study provided the first evidence that cox-2 was expressed in the ovine endometrium. We reported that cox-2 was not detected on days 0, 6, and 9, whereas it was highly expressed in the endometrium by day 12 of the estrous cycle and pregnancy. The endometrial cox-2 displayed a pattern of expression that is consistent with the inducible nature of cox-2 as usually described. In contrast, we found that ovine endometrial cox-1 was expressed at all stages of the estrous cycle and pregnancy with no major quantitative variations. This relatively constant level of expression agreed with the usual thinking that the cox-1 is constitutively synthesized in most tissues. Before the discovery of the two cyclooxygenase isoforms, the PG synthase enzyme had been studied in the ovine uterus. In a previous study, Huslig et al. (9) reported changes in PG synthase during the estrous cycle. They found that the activity of PG synthase measured in uterine microsomes was higher on days 13-15 of the estrous cycle. They concluded that the increase in enzymatic activity results from an increase in the concentration of the enzyme because the immunochemical equivalence points remained the same. However, using Northern blot analysis, opposite results were obtained by Salamonsen et al. (10) who found that no differences in PG synthase expression were observed throughout the estrous cycle or in early pregnancy. It is clear now that these authors (10) must have analyzed the cox-1 gene expression because they detected a mRNA of 2.8 kb, which is equivalent in size to the identified RNA transcript for cox-1 (38, 39) . However it should be noted that an additional hybridization band corresponding to mRNA of about 4.8 kb was described and was considered nonspecific hybridization. It seems likely that this mRNA would correspond to cox-2, which is 4.0 -4.5 kb in length (20, 40) . Taken together, these results and ours indicate that cox-1 is expressed at steady state levels in the ovine endometrium, whereas the levels of cox-2 expression undergo important changes.
The observation that cox-2 showed marked cyclical changes throughout the estrous cycle led us to examine the role of steroids on the expression of the two cyclooxygenases. In this study we have shown that endometrial cox-2 was primarily controlled by ovarian steroids because cox-2 was not expressed in the absence of steroids. Progesterone alone elicited high levels of endometrial cox-2, whereas endometria from ovariectomized ewes did not exhibit any detectable immunoreactive protein. We did not observe any significant effect of estrogen on cox-2 concentration. It could be assumed that in intact ewes, the exposure of the uterus to increasing concentrations of progesterone over 10 days is primarily responsible for the expression of cox-2. Other evidence for the role of progesterone in stimulating the expression of endometrial PG synthase comes from the in situ hybridization study of Eggleston et al. (41) . These authors reported an 8-fold increase in the level of hybridization signal of ewe uterine tissue sections following progesterone administration. They used a complementary RNA probe directed against the mRNA corresponding to the 438-to 455-amino acid region of mature ovine cox-1, which is 33% identical to the equivalent region of human cox-2. Such a riboprobe could hybridize with both mRNA for cox-1 and -2. Consequently it could be assumed that the increase in PG synthase signal observed by these authors after progesterone treatment was due more to an increase in cox-2 mRNA than to cox-1 mRNA.
If the induction of cox-2 expression seemed clearly dependent on progesterone, the regulation of the end of cox-2 expression was not clarified. The fact that on day 17 of pregnancy the expression of cox-2 was maintained, whereas it
Relationship between endometrial contents of cyclooxygenases and in vitro release of uterine PGF2␣. Endometrial explants were incubated for 6 h. PGF2␣ was measured in duplicate by RIA in incubation medium. Values were corrected for wet wt of incubated tissues. Cox-2 and -1 contents were determined in endometrium extracts (15 g) by Western blot using mAb294 (anticox-2) and L855 (anticox-1), respectively. Hybridization signals were quantified by scanning densitometry.
stopped in nonpregnant ewes, suggests that the drop in progesterone and the increase in estrogen that occurs at the end of the estrous cycle arrests cox-2 expression. However our results did not support this hypothesis. Actually, cox-2 was neither reduced when the progesterone treatment was stopped nor during the estradiol treatment that followed. In both cases the protein levels remained high. It is likely that other factors, which remained to be determined, are responsible for the cessation of cox-2 expression. In other species, recent reports have examined the relationship between the expression of uterine cox-2 and steroids. In the rat endometrium, Shoda et al. (42) observed that the induction of cox-2 coincided with the peak in serum estradiol levels, suggesting the estradiol-dependent induction of cox-2. However, in the mouse, Chakraborty et al. (27) failed to demonstrate an effect of steroid treatment on the induction of uterine cox-2.
Unlike cox-2, cox-1 was expressed in the absence of steroid treatment. Our results were consistent with those of Salamonsen et al. (10) who showed constitutive expression of PG synthase mRNA in both ovariectomized ewes and steroid treated animals. Our data indicated that the cox-1 levels were increased to a limited but significant extent by progesterone. However we did not observed any suppressive effect of estrogen on cox-1 expression as reported by Salamonsen et al. (10) .
Apart from their different modes of expression, the two isoforms also differed in their cellular localization. We showed that the cox-2 enzyme was strictly localized in the luminal cells and in the outer glands of the endometrium. However, it was primarily expressed in the caruncular epithelium, then in the epithelium of the intercaruncular area. As the estrous cycle advanced, the outer glands became increasingly stained but the deeper glands were always negative. In contrast, we did not observe any changes in the staining of cox-1, which was localized in both epithelial and stromal cells as well as in outer and deeper glands. Our results for the cox-2 staining agreed with those of Salamonsen et al. (43) who reported an equivalent continuum of change in PG synthase staining. It could be proposed that the mAb [cyo-1 from Dewitt et al. (44) ] that these authors used recognized both cox-1 and -2.
The presence of cox-2 in uterine tissues has been previously reported in rodents (26, 27, 42) and human decidual cells (45) . In the mouse, expression of cox-2 is related to the implantation of the blastocyst, because it is exclusively observed in the stromal and epithelial cells adjacent to the site of embryo attachment (26, 27) . In mice, the blastocyst appears to be directly responsible for the induction of cox-2 in the uterus. In sheep, our results indicated that the expression of cox-2 differed from that of the mouse. The induction of the enzyme did not require the presence of the blastocyst because cox-2 expression occurred in the uteri of cyclic ewes. Moreover, we did not observe cox-2 in the stromal compartment of the ovine endometrium. This difference in endometrial localization of cox-2 could be related to the mode of implantation of the trophoblast to the uterus. In rodents, the invasive trophoblast comes in close contact with the uterine stroma, whereas in ruminants, the trophoblast does not penetrate the stroma and is apposed to the maternal epithelium, which expresses cox-2. Thus endometrial cox-2 could be involved in the important changes in cellular adhesiveness at the time of implantation (reviewed in Ref. 46 ). Indeed, it has been recently demonstrated that strong expression of cox-2 increases adhesion to extracellular matrix proteins (47) .
We have shown that the release of PGF2␣ by endometrial explants is correlated with their cox-2 contents, suggesting that the increase in the ability of the uterus to produce PGs during the luteal phase of the estrous cycle is due to the increase in cox-2 levels. The ability of the enzyme to convert arachidonic acid seems to be unaffected by pregnancy because PGF2␣ was released in the culture medium at the same rate from pregnant and nonpregnant endometrial explants. These findings are consistent with the current agreement that pregnant and nonpregnant endometria have similar abilities to synthesize PGs (48, 2) . It has been well demonstrated that FIG. 8 . Effect of steroid treatments on cox-2 and -1 expression in endometrium of ovariectomized ewes. Cox-2 and -1 were analyzed by Western blot on endometrial extracts of 1) three control groups: untreated (C), progestagen pretreated (C-P), progestagen and estradiol pretreated (C-E) ewes; 2 four experimental groups: progesterone treatment for 10 days (P10) followed by estradiol administrated on days 11 and 12 (P10-E), progesterone treatment for 12 days (P12) with estradiol administration on day 11 and 12 (P12-E). Immunoblots of one representative extract of each treatment group are shown. Quantification of cox-2 and -1 was determined by scanning densitometry of enhanced chimioluminescence signals. Values are means Ϯ SD of relative density (n ϭ 3).
in vivo the patterns of secretion differ but there is no difference in the mean concentrations of PGF2␣ (2) . It is of interest to note that cox-2 was expressed in high concentrations close to the time when the luteolysis process occurs. It could be suggested that cox-2 function is to induce the high burst of PGF2␣ required for the completion of luteolysis. However, the persistence of high concentrations of cox-2 in early pregnancy brings into question the physiological significance of the prostanoids formed. It could be suggested that the generation of a PG-generating system is not only relevant to the luteolysis process but argues in favor of a role for PGs in the establishment of pregnancy.
In conclusion, to appreciate the biological relevance of cox-2 expression it should be noted that, in the ewe, there are two physiological situations in which the synthesis of PGs needs to be strictly regulated, i.e. luteolysis and parturition, and that these two require require the induction of cox-2. In addition, because the endometrium and placenta are two tissues particularly sensitive to steroids, the ewe appears to be a suitable model for the hormonal regulation of cox-2.
